ZyVersa Therapeutics Announces Research Published in Frontiers in Immunology Reinforcing IC 100's Rationale for Inhibiting Multiple Inflammasomes to Control Inflammation in Various Inflammatory DiseasesGlobeNewsWire • 09/12/23
ZyVersa Therapeutics Reports Second Quarter 2023 Corporate and Financial ResultsGlobeNewsWire • 08/21/23
ZyVersa Therapeutics Announces Publication in the Journal, Hepatology, Highlighting the Role of NLRP3 Inflammasome-Mediated IL-18 in Development of Liver FibrosisGlobeNewsWire • 07/15/23
ZyVersa Therapeutics Announces Publication in the Journal Circulation That Demonstrates the Role of Inflammasome Activation in Hypertrophic Heart Disease Induced by Mechanical StressGlobeNewsWire • 07/10/23
European Patent Granted for ZyVersa Therapeutics' Lead Asset, Cholesterol Efflux Mediator™ VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney DiseaseGlobeNewsWire • 07/07/23
ZyVersa Therapeutics Announces Publication in Clinical Immunology Demonstrating Association Between Renal NLRP3 Inflammasome Activation and Lupus Nephritis Disease ActivityGlobeNewsWire • 06/28/23
ZyVersa Therapeutics Announces a Publication in Journal of the American Heart Association Linking NLRP3 Inflammasomes with Calcification in Arteries of Patients with Peripheral Arterial Disease (PAD)GlobeNewsWire • 06/20/23
ZyVersa Therapeutics Publishes New White Paper Detailing the Critical Role of Inflammasome ASC in Inflammatory Diseases, and Its Potential as a Therapeutic TargetGlobeNewsWire • 06/13/23
European Patent Office to Grant ZyVersa Therapeutics' Patent Application for Cholesterol Transport Mediator™ VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney DiseaseGlobeNewsWire • 06/06/23
ZyVersa Therapeutics Announces a Publication in Frontiers in Medicine Showing Direct Inflammasome Activation in Children with Juvenile Idiopathic ArthritisGlobeNewsWire • 05/25/23
ZyVersa Therapeutics Announces Article Published in Metabolism Pointing to Glomerular Cholesterol Accumulation as Key Factor Exacerbating Renal Injury and Dysfunction in Diabetic Kidney DiseaseGlobeNewsWire • 05/15/23
ZyVersa Therapeutics Reports First Quarter 2023 Corporate and Financial ResultsGlobeNewsWire • 05/12/23
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2023 BIO International ConventionGlobeNewsWire • 05/09/23
ZyVersa Therapeutics Announces a Publication in Hepatology Revealing That Alcohol-induced Extracellular ASC Specks Perpetuate Liver Inflammation and Damage in Alcoholic HepatitisGlobeNewsWire • 05/04/23
ZyVersa Therapeutics, Inc. Announces Closing of $11.0 Million Public OfferingGlobeNewsWire • 05/01/23
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at Sidoti Micro-Cap Virtual ConferenceGlobeNewsWire • 04/27/23
ZyVersa Therapeutics, Inc. Announces Pricing of $11.0 Million Public OfferingGlobeNewsWire • 04/26/23
ZyVersa Therapeutics Announces Publication of an Article in the Journal of Neuroinflammation Addressing the Role of ASC Specks in Propagation of Alpha-Synuclein Pathology in Parkinson's DiseaseGlobeNewsWire • 04/25/23
ZyVersa Therapeutics Adds Dr. Douglas Golenbock to Its Inflammatory Disease Scientific Advisory Board to Support Advancement of Inflammasome ASC Inhibitor IC 100GlobeNewsWire • 04/24/23
